97 related articles for article (PubMed ID: 7988721)
61. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Rustamzadeh E; Li C; Doumbia S; Hall WA; Vallera DA
J Neurooncol; 2003 Oct; 65(1):63-75. PubMed ID: 14649886
[TBL] [Abstract][Full Text] [Related]
62. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme.
Kirchheimer JC; Christ G; Binder BR
Eur J Biochem; 1989 Apr; 181(1):103-7. PubMed ID: 2540964
[TBL] [Abstract][Full Text] [Related]
63. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule.
Dear AE; Medcalf RL
Eur J Biochem; 1998 Mar; 252(2):185-93. PubMed ID: 9523687
[TBL] [Abstract][Full Text] [Related]
64. Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells.
Dumler I; Petri T; Schleuning WD
FEBS Lett; 1994 Apr; 343(2):103-6. PubMed ID: 8168613
[TBL] [Abstract][Full Text] [Related]
65. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
66. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].
Zhu F; Xing G; He F
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013
[TBL] [Abstract][Full Text] [Related]
67. A novel tumor targeting drug carrier for optical imaging and therapy.
Li R; Zheng K; Hu P; Chen Z; Zhou S; Chen J; Yuan C; Chen S; Zheng W; Ma E; Zhang F; Xue J; Chen X; Huang M
Theranostics; 2014; 4(6):642-59. PubMed ID: 24723985
[TBL] [Abstract][Full Text] [Related]
68. Construction of antisense RNA expression plasmid for u-PAR and its transfection to highly invasive PC-3M cell subclones.
Liao G; Li Q; Feng Y; Deng Y; Li Z; Gong F; Ma D
J Huazhong Univ Sci Technolog Med Sci; 2003; 23(4):369-72. PubMed ID: 15015638
[TBL] [Abstract][Full Text] [Related]
69. Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release.
Li S; Yuan C; Chen J; Chen D; Chen Z; Chen W; Yan S; Hu P; Xue J; Li R; Zheng K; Huang M
Theranostics; 2019; 9(3):884-899. PubMed ID: 30809315
[TBL] [Abstract][Full Text] [Related]
70. Inhibition of urokinase synthesis and cell surface binding alters the motile behavior of embryonic endocardial-derived mesenchymal cells in vitro.
McGuire PG; Alexander SM
Development; 1993 Jul; 118(3):931-9. PubMed ID: 8076527
[TBL] [Abstract][Full Text] [Related]
71. The cloning, isolation and characterization of a biologically active human enzyme, urokinase, in E. coli.
Hung PP
Adv Exp Med Biol; 1984; 172():281-93. PubMed ID: 6375302
[TBL] [Abstract][Full Text] [Related]
72. Increasing gene expression in yeast by fusion to ubiquitin.
Ecker DJ; Stadel JM; Butt TR; Marsh JA; Monia BP; Powers DA; Gorman JA; Clark PE; Warren F; Shatzman A
J Biol Chem; 1989 May; 264(13):7715-9. PubMed ID: 2540202
[TBL] [Abstract][Full Text] [Related]
73. A versatile insertion point on albumin to accommodate peptides and maintain their activities.
Huang Z; Lin H; Yu S; Li H; Zhou Y; Cheng Y; Chen S; Yuan C; Huang M
Int J Biol Macromol; 2022 Apr; 205():49-54. PubMed ID: 35134454
[TBL] [Abstract][Full Text] [Related]
74. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor.
Palwai NR; Zang XP; Harrison RG; Benbrook D; Pento JT
Pharmacology; 2009; 84(5):271-5. PubMed ID: 19797936
[TBL] [Abstract][Full Text] [Related]
75. Pro-urokinase promotes angiogenesis but does not reduce neuronal apoptosis in infarcted cerebral tissue.
Qin W; Yang L; Guo H; Xiang N; Hu W
Neural Regen Res; 2014 Mar; 9(5):502-3. PubMed ID: 25206846
[No Abstract] [Full Text] [Related]
76. Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy.
Li D; Liu S; Shan H; Conti P; Li Z
Theranostics; 2013; 3(7):507-15. PubMed ID: 23843898
[TBL] [Abstract][Full Text] [Related]
77. The inhibitory effects of an antisense u-PAR vector on invasion of highly invasive human prostate carcinoma PC-3M cell subclones.
Liao G; Li Q; Feng Y; Deng Y; Li Z; Gong F; Ma D
J Huazhong Univ Sci Technolog Med Sci; 2003; 23(2):101-4. PubMed ID: 12973920
[TBL] [Abstract][Full Text] [Related]
78. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.
Ignar DM; Andrews JL; Witherspoon SM; Leray JD; Clay WC; Kilpatrick K; Onori J; Kost T; Emerson DL
Clin Exp Metastasis; 1998 Jan; 16(1):9-20. PubMed ID: 9502073
[TBL] [Abstract][Full Text] [Related]
79. Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin.
Lu H; Yeh P; Guitton JD; Mabilat C; Desanlis F; Maury I; Legrand Y; Soria J; Soria C
FEBS Lett; 1994 Dec; 356(1):56-9. PubMed ID: 7988721
[TBL] [Abstract][Full Text] [Related]
80. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
